Clinical Trial Update: Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial comparing autogenic versus allogenic NK immunotherapy for recurrent solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumours

Drugs mentioned

• allogenic NK immunotherapy
• autogenic NK immunotherapy

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Malignant Solid Tumour | Phase 2 | Status: COMPLETED